LFG316
Sponsors
Novartis Pharmaceuticals, Alcon Research
Conditions
Advanced Age-related Macular DegenerationAge-related Macular DegenerationExudative Macular DegenerationGeographic AtrophyKidney TransplantationNeovascular Age-elated Macular Degeneration (Wet AMD)Neovascular Age-related Macular DegenerationNon-infectious Intermediate Uveitis
Phase 1
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
CompletedNCT01255462
Start: 2010-11-30End: 2011-09-30Updated: 2012-05-01
Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316
CompletedNCT02878616
Start: 2016-08-26End: 2017-07-19Updated: 2020-12-11
Phase 2
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
CompletedNCT01526889
Start: 2012-12-20End: 2017-08-24Updated: 2021-01-05
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
CompletedNCT01527500
Start: 2012-01-25End: 2015-06-24Updated: 2021-01-05
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
CompletedNCT01535950
Start: 2012-02-29End: 2013-07-31Updated: 2020-12-19
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
TerminatedNCT01624636
Start: 2012-12-31End: 2013-05-31Updated: 2020-12-19
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
CompletedNCT02515942
Start: 2015-09-25End: 2017-12-01Updated: 2019-05-30
Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
CompletedNCT02534909
Start: 2015-09-09End: 2022-05-24Updated: 2025-05-16